2g69: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="2g69" size="450" color="white" frame="true" align="right" spinBox="true" caption="2g69, resolution 1.35Å" /> '''Structure of Unliga...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:2g69.gif|left|200px]]<br />
[[Image:2g69.gif|left|200px]]<br /><applet load="2g69" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2g69" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2g69, resolution 1.35&Aring;" />
caption="2g69, resolution 1.35&Aring;" />
'''Structure of Unliganded HIV-1 Protease F53L Mutant'''<br />
'''Structure of Unliganded HIV-1 Protease F53L Mutant'''<br />


==Overview==
==Overview==
Mutations in HIV-1 protease (PR) that produce resistance to antiviral PR, inhibitors are a major problem in AIDS therapy. The mutation F53L arising, from antiretroviral therapy was introduced into the flexible flap region, of the wild-type PR to study its effect and potential role in developing, drug resistance. Compared to wild-type PR, PR(F53L) showed lower (15%), catalytic efficiency, 20-fold weaker inhibition by the clinical drug, indinavir, and reduced dimer stability, while the inhibition constants of, two peptide analog inhibitors were slightly lower than those for PR. The, crystal structure of PR(F53L) was determined in the unliganded form at, 1.35 Angstrom resolution in space group P4(1)2(1)2. The tips of the flaps, in PR(F53L) had a wider separation than in unliganded wild-type PR, probably due to the absence of hydrophobic interactions of the side-chains, of Phe53 and Ile50'. The changes in interactions between the flaps agreed, with the reduced stability of PR(F53L) relative to wild-type PR. The, altered flap interactions in the unliganded form of PR(F53L) suggest a, distinct mechanism for drug resistance, which has not been observed in, other common drug-resistant mutants.
Mutations in HIV-1 protease (PR) that produce resistance to antiviral PR inhibitors are a major problem in AIDS therapy. The mutation F53L arising from antiretroviral therapy was introduced into the flexible flap region of the wild-type PR to study its effect and potential role in developing drug resistance. Compared to wild-type PR, PR(F53L) showed lower (15%) catalytic efficiency, 20-fold weaker inhibition by the clinical drug indinavir, and reduced dimer stability, while the inhibition constants of two peptide analog inhibitors were slightly lower than those for PR. The crystal structure of PR(F53L) was determined in the unliganded form at 1.35 Angstrom resolution in space group P4(1)2(1)2. The tips of the flaps in PR(F53L) had a wider separation than in unliganded wild-type PR, probably due to the absence of hydrophobic interactions of the side-chains of Phe53 and Ile50'. The changes in interactions between the flaps agreed with the reduced stability of PR(F53L) relative to wild-type PR. The altered flap interactions in the unliganded form of PR(F53L) suggest a distinct mechanism for drug resistance, which has not been observed in other common drug-resistant mutants.


==About this Structure==
==About this Structure==
2G69 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2G69 OCA].  
2G69 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2G69 OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Human immunodeficiency virus 1]]
[[Category: Human immunodeficiency virus 1]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Kovalevsky, A.Y.]]
[[Category: Kovalevsky, A Y.]]
[[Category: Liu, F.]]
[[Category: Liu, F.]]
[[Category: aspartic protease]]
[[Category: aspartic protease]]
Line 23: Line 22:
[[Category: unliganded]]
[[Category: unliganded]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov  8 14:48:22 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:28:32 2008''